PriceTargets.com logo

Hill-Rom - HRC Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$155.96 As of 12/13/2021 01:00 AM ET
+0 (0.00%)
Get New Hill-Rom Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HRC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HRC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Hill-Rom in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $155.96.

This chart shows the closing price for HRC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Hill-Rom. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/5/2021Stifel NicolausDowngradeBuy ➝ Hold$155.00
9/19/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$148.00 ➝ $156.00
9/8/2021KeyCorpDowngradeOverweight ➝ Sector Weight
9/3/2021Robert W. BairdDowngradeOutperform ➝ Neutral$150.00 ➝ $156.00
8/10/2021Bank of AmericaDowngradeBuy ➝ Neutral$130.00
8/2/2021Morgan StanleyBoost TargetOverweight$130.00 ➝ $148.00
8/2/2021Robert W. BairdBoost TargetOutperform$125.00 ➝ $150.00
8/2/2021KeyCorpBoost TargetOverweight$131.00 ➝ $145.00
5/3/2021Raymond JamesBoost TargetOutperform$120.00 ➝ $122.00
5/3/2021Robert W. BairdBoost TargetOutperform$115.00 ➝ $125.00
2/16/2021Raymond JamesBoost TargetOutperform$113.00 ➝ $120.00
2/8/2021Raymond JamesBoost TargetOutperform$107.00 ➝ $113.00
2/8/2021Morgan StanleyBoost TargetOverweight$125.00 ➝ $130.00
2/8/2021Robert W. BairdBoost TargetOutperform$105.00 ➝ $115.00
12/15/2020Morgan StanleyBoost TargetOverweight$110.00 ➝ $125.00
11/9/2020Raymond JamesBoost TargetOutperform$100.00 ➝ $107.00
11/4/2020Needham & Company LLCDowngradeBuy ➝ Hold
10/12/2020Raymond JamesLower TargetOutperform$115.00 ➝ $100.00
10/1/2020KeyCorpLower TargetOverweight$138.00 ➝ $115.00
9/29/2020Needham & Company LLCLower TargetBuy$129.00 ➝ $117.00
9/21/2020Morgan StanleyLower TargetOverweight$112.00 ➝ $110.00
9/16/2020Raymond JamesReiterated RatingBuy
9/1/2020Robert W. BairdInitiated CoverageOutperform$115.00
8/3/2020Morgan StanleyLower TargetOverweight$123.00 ➝ $112.00
8/3/2020Raymond JamesLower TargetOutperform$120.00 ➝ $115.00
8/3/2020KeyCorpLower TargetOverweight$140.00 ➝ $138.00
7/31/2020Needham & Company LLCLower TargetBuy$131.00 ➝ $129.00
5/4/2020UBS GroupLower TargetBuy$130.00 ➝ $125.00
4/14/2020BarclaysReiterated RatingBuy$125.00
3/27/2020Morgan StanleyLower TargetOverweight$138.00 ➝ $125.00
3/17/2020BarclaysUpgradeEqual Weight ➝ Overweight$116.00
1/24/2020Needham & Company LLCReiterated RatingBuy$131.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Hill-Rom logo
Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.
Read More

Today's Range

Now: $155.96
Low: $155.96
High: $155.96

50 Day Range

MA: $155.74
Low: $155.05
High: $156.18

52 Week Range

Now: $155.96
Low: $93.34
High: $156.22

Volume

N/A

Average Volume

656,912 shs

Market Capitalization

$10.30 billion

P/E Ratio

41.92

Dividend Yield

0.62%

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Hill-Rom?

The following sell-side analysts have issued stock ratings on Hill-Rom in the last twelve months: StockNews.com.
View the latest analyst ratings for HRC.

What is the current price target for Hill-Rom?

0 Wall Street analysts have set twelve-month price targets for Hill-Rom in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Hill-Rom in the next year.
View the latest price targets for HRC.

What is the current consensus analyst rating for Hill-Rom?

Hill-Rom currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HRC.

What other companies compete with Hill-Rom?

Other companies that are similar to Hill-Rom include IDEXX Laboratories, ResMed, DexCom, STERIS and Insulet. Learn More about companies similar to Hill-Rom.

How do I contact Hill-Rom's investor relations team?

Hill-Rom's physical mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company's listed phone number is (312) 819-7200 and its investor relations email address is [email protected]. The official website for Hill-Rom is www.hill-rom.com. Learn More about contacing Hill-Rom investor relations.